CyFlow CD23 PE-Cy7
| 品番 | CH091551 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD23 PE-CY7,EBVCS-5 | ||
| 包装単位 | 100 tests | ||
| 濃度 | - | ||
| 容量 | 0.4 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 PE-Cy7 (CF148611) |
||
| 反応性|交差吸着 | Human | レーザー | Blue, Green, Yellow |
| 抗原 | CD23, FcɛRII , BLAST-2 | 最大蛍光波長 | 785 nm |
| クローン | EBVCS-5 | 最大励起波長 | 496 nm, 565 nm |
| ホスト | Mouse | 標識/Format | PE-Cy7 |
| アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD23 PE-CY7,EBVCS-5
特異性
The mouse monoclonal antibody EBVCS-5 recognizes an epitope located in the stalk region of human low affinity IgE receptor (CD23) between the 37 and 25 kDa cleavage sites.
抗原情報
CD23 (Fc ε RII), the low affinity IgE receptor, is a 45 kDa type II membrane glycoprotein expressed more or less on eosinophils, follicular dendritic cells, Langerhans cells, mature B cells (mainly upon activation), EBV-transformed lymphoblasts, monocytes, and subpopulation of platelets. A soluble form of 37 kDa and other its fragments were also described. CD23 mediates IgE-dependent cytotoxicity by eosinophils and macrophages, and downregulates IgE secretion in response to high levels of IgE, involving release of pro-inflammatory cytokines.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Belleau JT, Gandhi RK, McPherson HM, Lew DB: Research upregulation of CD23 (FcepsilonRII) expression in human airway smooth muscle cells (huASMC) in response to IL‑4, GM‑CSF, and IL‑4/GM‑CSF. Clin·Mol·Allergy. 2005·May·20; 3:6. <·PMID:·15907205·>
• Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin·Cancer·Res. 2007·Aug·1; 13(15‑1):4448‑55. <·PMID:·17671129·>
• Ling NR, Stevenson FK, Brown B: Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL). Clin·Exp·Immunol. 1991·Dec; 86(3):360‑6. <·PMID:·1721010·>
• Rumi C, Rutella S, Leone G, Bonini S: Fc‑RII/CD23 receptor on circulating human eosinophils. Blood. 1998·Apr·1; 91(7):2621‑2. <·PMID:·9516167·>
• Yamaoka KA, Arock M, Issaly F, Dugas N, Le Goff L, Kolb JP: Granulocyte macrophage colony stimulating factor induces Fc epsilon RII/CD23 expression on normal human polymorphonuclear neutrophils. Int·Immunol. 1996·Apr; 8(4):479‑90. <·PMID:·8722638·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN